Correction of peroxidation of lipids with upadacitinib, a Janus kinase 1 inhibitor, in patients with true eczema

DOI: https://doi.org/10.29296/25877305-2023-04-14
Issue: 
4
Year: 
2023

Professor L. Novikova, MD; Professor E. Dontsova, MD; Professor O. Saurina, MD; Professor A. Chernov, MD; Professor V. Dontsov, MD; Associate Professor
L. Borzunova, Candidate of Medical Sciences; T. Pogodaeva
N.N. Burdenko Voronezh State Medical University, Ministry of Health of Russia

Objective. To study the effect of upadacitinib (UPA), a Janus kinase inhibitor 1 kinase, on the status of peroxidation of lipids (POL) and the antioxidant system in patients with true eczema. Subjects and methods. The investigation involved 64 patiens (43 males and 21 females) with true eczema (the mean age was 58.5±3.4 years). The patients were randomized into 2 groups: 1) 33 patients who received basic drug therapy (BDT); 2) 31 patients who received the Janus kinase 1 inhibitor UPA 15 mg/day during 2 months. The components of the antioxidant system and the state of POL were determined by enzyme immunoassay. Results. After 2 months of therapy, Group 1 showed no statistically significant changes in the analyzed parameters from the baseline level (p>0.05). In Group 2, the total oxidative capacity of blood reduced by 1.27 tines; the level of oxidized low-density lipoproteins decreased by 1.28 times; the total antioxidant activity of blood increased by 1.24 times; the level of superoxidase dismutase increased by 1.43 times (p < 0.001 for all values). Conclusion. The combined use of BDT and the JAK1 inhibitor UPA in patients with true eczema contributed to a statistically significant decline in the oxidative capacity of blood and POL products along with the enhanced antioxidant activity of blood.
Keywords: 
dermatology
true eczema
lipid peroxidation
upadacinib

References: 
  1. Sohn A., Frankel A., Patel R.V. et al. Eczema. Mt Sinai J Med. 2011; 78 (5): 730–9. DOI: 10.1002/msj.20289
  2. Земсков А.М., Земсков В.М., Земскова В.А. и др. Метаболический иммунитет. Вестник Воронежского государственного университета. Серия: Химия. Биология. Фармация. 2016; 2: 41–9 [Zemskov A.M., Zemskov V.M., Zemskova V.A. et al. Metabolic immunity. Bulletin of the Voronezh State University. Series: Chemistry. Biology. Pharmacy. 2016; 2: 41–9 (in Russ.)].
  3. Веремейчик А.П. Особенности процессов перекисного окисления липидов и антиоксидантной системы у больных экземой на фоне лазеротерапии. Медицинский журнал. 2006; 2: 29–31 [Veremeychik A.P. Features of lipid peroxidation and antioxidant system processes in patients with eczema on the background of laser therapy. Medical Journal. 2006; 2: 29–31 (in Russ.)].
  4. Bashura O.G., Mirgorod V.S., Bobro S.G. Дослідження ринку лікарських препаратів, які застосовуються для місцевого лікування дерматитів. Management, economy and quality assurance in pharmacy. 2019; 3 (59): 48–54 [Bashura O.G., Mirgorod V.S., Bobro S.G. Market research of medicines used for topical treatment of dermatitis. Management, economy and quality assurance in pharmacy. 2019; 3 (59): 48–54 (in Ukrainian)].
  5. Исаков С.А., Амозова И.В., Белотелова Л.К. и др. Активность супероксиддисмутазы, каталазы и глутатионпероксидазы у больных атопическим дерматитом и хронической экземой как показатель свободнорадикального статуса крови. Вестник дерматологии и венерологии. 2005; 4: 23–4 [Isakov S.A., Amozova I.V., Belotelova L.K. et al. Activity of superoxide dismutase, catalase and glutathione peroxidase in patients with atopic dermatitis and chronic eczema as an indicator of free radical blood status. Bulletin of Dermatology and Venereology. 2005; 4: 23–4 (in Russ.)].
  6. Паращук Б.М., Асцатуров Г.Е., Билинская О.А. Влияние антиоксидантов на коррекцию перекисного окисления липидов у больных экземой. Дерматовенерология. Косметология. Сексопатология. 2010; 3–4: 79–82 [Parashchuk B.M., Astsaturov G.E., Bilinskaya O.A. The antioxidants effect on the correction of lipid peroxidation in patients with eczema. Dermatovenerology. Cosmetology. Sexopathology. 2010; 3–4: 79–82 (in Ukrainian)].
  7. Адаскевич В.П. Дерматовенерология. М.: Мед. лит., 2019; 408 с. [Adaskevich V.P. Dermatovenerology. M.: Med. Lit., 2019; 408 p. (in Russ.)].
  8. Экзема. Клинические рекомендации. Минздрав России, 2021 [Eczema. Clinical recommendations. Ministry of Health of the Russian Federation, 2021 (in Russ.)]. URL: https://www.rodv.ru/upload/iblock/698/69814889b9519ed73c8ba7c0c7bc4b35.pdf
  9. Ковалева Ю.С., Оробей М.В., Зяблицкая Н.К. Селективный обратимый ингибитор JAK1 в терапии среднетяжелого и тяжелого атопического дерматита. Медицинский совет. 2022; 16 (3): 103–10 [Kovaleva Yu.S., Orobei M.V., Zyablitskaya N.K. Selective reversible JAK1 inhibitor in the treatment of moderate and severe atopic dermatitis. Meditsinskiy Sovet. 2022; 16 (3): 103–10 (in Russ.)]. DOI: 10.21518/2079-701X-2022-16-3-103-110
  10. Ревякина В.А., Мухортых В.А., Ларькова И.А. и др. Успешное применение ингибитора янус-киназ для лечения атопического дерматита. Российский педиатрический журнал. 2022; 25 (4): 225–9 [Revyakina V.A., Mukhortykh V.A., Larkova I.A. et al. Successful use of a janus kinase inhibitor for the treatment of atopic dermatitis. Russian Pediatric Journal. 2022; 25 (4): 225–9 (in Russ.)]. DOI: 10.46563/1560-9561-2022-25-4-225-229